How Many Doses in a Vial of Hexarelin? (Dosing Breakdown)

A 2mg lyophilised Hexarelin vial doesn't come with pre-measured doses. The number of doses you extract depends entirely on how much bacteriostatic water you add during reconstitution and what target dose your protocol requires. Most research labs targeting 200mcg per administration will extract 10 doses from a single 2mg vial when reconstituted with 2mL of bacteriostatic water, but protocols using 100mcg doses double that yield to 20 doses from the same vial. The arithmetic is straightforward, but the margin for error is narrow. A miscalculation at the reconstitution stage compounds across every subsequent draw, rendering your entire dosing schedule unreliable.

Our team has guided researchers through peptide preparation for years. The gap between reproducible results and wasted vials comes down to three things most protocols overlook: precise reconstitution volume measurement, correct syringe selection for target dose extraction, and understanding that peptide concentration isn't fixed. You define it during mixing.

How many doses are in a vial of Hexarelin?

A standard 2mg Hexarelin vial yields 10–40 doses depending on reconstitution volume and target dose per administration. Reconstituting with 2mL bacteriostatic water creates a 1mg/mL solution. At 200mcg per dose, you extract 10 doses; at 100mcg per dose, you extract 20 doses. The vial's total peptide content is fixed, but dose count is variable and protocol-dependent.

Most researchers don't realise the vial itself contains no predetermined dose structure. You're not drawing from pre-portioned units. You're extracting a calculated volume from a solution you created. This means every dose's accuracy depends on two steps performed correctly: measuring reconstitution liquid to the exact millilitre, and drawing the precise syringe volume that corresponds to your target microgram dose. Miss either step and your entire protocol drifts off baseline. This article covers how reconstitution volume determines dose yield, how to calculate exact syringe draw volumes for target doses, and what preparation errors silently compromise data quality before the first administration.

Reconstitution Volume Determines Dose Count — Not the Vial Size

The 2mg label on a Hexarelin vial tells you total peptide mass, not how many administrations that mass supports. A researcher targeting 200mcg doses will exhaust the vial in 10 draws, while a protocol requiring 100mcg doses stretches the same vial to 20 administrations. The difference isn't the peptide. It's the liquid volume you add during reconstitution, which sets the concentration (mg/mL), and the target dose, which dictates how much of that solution you draw per administration. Reconstitute 2mg Hexarelin with 1mL bacteriostatic water and you create a 2mg/mL solution; reconstitute with 2mL and you create a 1mg/mL solution. Same peptide, different concentration, different syringe volumes required to hit the same microgram target.

Our experience with research-grade peptides shows that the single most common dosing error occurs at reconstitution. Not administration. Adding 1.8mL when the protocol calls for 2.0mL shifts your effective concentration by 10%, meaning every subsequent draw delivers 10% more peptide than intended. Over a 20-dose protocol, that's cumulative protocol drift severe enough to invalidate cross-trial comparisons. Standard reconstitution for Hexarelin uses 2mL bacteriostatic water per 2mg vial, yielding 1mg/mL (1000mcg/mL). At this concentration, a 200mcg dose requires a 0.2mL (20-unit) syringe draw, and a 100mcg dose requires 0.1mL (10 units). The math is linear, but execution requires insulin syringes marked in 0.01mL increments. Standard 1mL syringes lack the granularity for sub-0.1mL precision.

Standard Dose Ranges and Corresponding Vial Yield

Research protocols for Hexarelin typically range from 100mcg to 300mcg per administration, with 200mcg being the most commonly cited dose in published studies examining growth hormone secretagogue effects. At 200mcg per dose, a single 2mg vial reconstituted with 2mL bacteriostatic water yields exactly 10 administrations. Protocols using 100mcg doses. Common in studies evaluating dose-response curves or minimising side effect profiles. Double that yield to 20 administrations per vial. Higher-dose protocols at 300mcg reduce yield to approximately 6–7 administrations, though doses above 200mcg are less frequently cited in peer-reviewed literature due to diminishing marginal returns on GH pulse amplitude and increased incidence of cortisol and prolactin elevation.

The table below maps target dose to vial yield for a standard 2mg Hexarelin vial reconstituted with 2mL bacteriostatic water (1mg/mL final concentration):

Dose count isn't speculative. It's arithmetic. A 2mg vial contains 2000mcg of peptide. Divide 2000mcg by your target dose and you get maximum administrations. Reconstitution volume doesn't change total peptide mass, but it does change the syringe volume you draw to extract that target dose, which affects ease of measurement precision. Drawing 0.1mL with an insulin syringe is straightforward; drawing 0.05mL approaches the lower limit of reliable measurement without specialized microliter syringes.

How Many Doses in a Vial of Hexarelin: Calculation Walkthrough

Calculating doses per vial requires three inputs: total peptide mass (mg), reconstitution volume (mL), and target dose (mcg). The process is two-step: first, calculate concentration after reconstitution; second, determine syringe draw volume for the target dose. For a 2mg Hexarelin vial reconstituted with 2mL bacteriostatic water, concentration equals 2mg ÷ 2mL = 1mg/mL, which converts to 1000mcg/mL. If your protocol targets 200mcg per dose, divide target dose by concentration: 200mcg ÷ 1000mcg/mL = 0.2mL per dose. Total doses equals total peptide mass divided by target dose: 2000mcg ÷ 200mcg = 10 doses.

This walkthrough applies universally across peptide types and vial sizes. A 5mg vial reconstituted with 2mL yields 2.5mg/mL (2500mcg/mL); at 200mcg per dose, you draw 0.08mL per administration for 25 total doses. The calculation is protocol-agnostic, but reconstitution precision is not. Measuring 2.0mL bacteriostatic water with a standard oral syringe introduces ±0.1mL error. A 5% concentration variance that cascades across every dose. Research-grade reconstitution uses graduated glass syringes or calibrated pipettes to eliminate volumetric guesswork. Our team has found that even experienced researchers underestimate how much a 0.1mL reconstitution error compounds over a 20-dose protocol. The cumulative deviation can exceed 10% by the final administration, enough to skew dose-response data in multi-arm studies.

For researchers working with non-standard vial sizes, the formula adapts directly. A 10mg vial reconstituted with 5mL yields 2mg/mL (2000mcg/mL). At 200mcg per dose, you draw 0.1mL per administration for 50 total doses. Larger vials improve cost-per-dose economics but introduce storage duration risk. Once reconstituted, peptides degrade over time even under refrigeration, and a 50-dose vial requires 50 administrations before the 28-day stability window closes.

Hexarelin: [Product] Comparison

Hexarelin sits in the high-amplitude, high-cortisol quadrant of the GH secretagogue landscape. It matches GHRP-6 for GH pulse strength but introduces cortisol co-release that GHRP-6 avoids and that Ipamorelin almost entirely eliminates. The practical consequence: Hexarelin protocols often cycle on-off to manage desensitization and cortisol exposure, while Ipamorelin supports continuous use with less receptor fatigue. For researchers prioritising maximal GH response in short-duration studies, Hexarelin delivers. For protocols extending beyond 4–6 weeks, Ipamorelin or GHRP-2 may offer better risk-benefit profiles. Our Hexarelin product undergoes small-batch synthesis with exact amino-acid sequencing, guaranteeing purity and consistency across every vial. The kind of reliability that matters when dose precision determines data validity.

What If: Hexarelin Dosing Scenarios

What If I Accidentally Add 1.8mL Instead of 2.0mL During Reconstitution?

Your effective concentration increases to 1.11mg/mL instead of 1.0mg/mL, meaning every 0.2mL draw now delivers 222mcg instead of 200mcg. An 11% overdose per administration. If precision matters to your protocol, discard the vial and reconstitute a fresh one. If you're running an exploratory study where ±10% variance is acceptable, document the actual concentration and adjust your syringe draw volume to 0.18mL to compensate (200mcg ÷ 1111mcg/mL = 0.18mL). The math works, but introducing compensation math mid-protocol introduces human error risk that clean reconstitution avoids entirely.

What If My Protocol Requires 150mcg Doses — How Many Doses Per Vial?

Divide total peptide mass by target dose: 2000mcg ÷ 150mcg = 13.3 doses, which rounds down to 13 full administrations per 2mg vial. At 1mg/mL concentration (2mL reconstitution), each 150mcg dose requires a 0.15mL syringe draw. The fractional 0.3-dose remainder (50mcg) isn't enough for a 14th administration at target dose, so practical yield is 13 doses. Attempting to extract a 14th partial dose introduces dosing inconsistency. Better to plan vial purchases around exact dose multiples.

What If the Peptide Looks Cloudy After Reconstitution?

Cloudiness indicates incomplete dissolution, potential contamination, or peptide aggregation. All of which compromise dosing accuracy and may reflect compromised product integrity. Do not administer cloudy solution. Hexarelin should dissolve completely into a clear, colourless solution within 60 seconds of gentle swirling (never shake. Shaking denatures peptide structures). If cloudiness persists after two minutes of gentle agitation, the vial is unusable. Possible causes include bacterial contamination in the bacteriostatic water, temperature excursion during storage that partially denatured the lyophilised powder, or manufacturing defect. Discard the vial and document the batch number. Reputable suppliers like Real Peptides stand behind product quality and will replace compromised vials when batch integrity is questioned.

The Unforgiving Truth About Hexarelin Dosing

Here's the honest answer: most dosing errors don't happen during administration. They happen during reconstitution, and you won't know you made one until your data doesn't replicate across trials. Hexarelin's dose-response curve is steep enough that a 10% concentration error produces measurable differences in GH pulse amplitude, and those differences show up as unexplained variance when you compare Week 1 results to Week 4 results from what you thought was the same protocol. The margin for error is narrow because the therapeutic window is narrow. 200mcg produces a robust GH pulse, 300mcg adds cortisol co-release without proportional GH benefit, and 100mcg underdelivers on the primary endpoint most studies are designed to measure. You don't get to approximate your way through peptide reconstitution and expect reproducible results.

The industry reality is that lyophilised peptides give researchers control over dosing precision, but only if that control is exercised at every step. Pre-filled syringes remove dosing variability but cost 3–4× more per administration and eliminate protocol flexibility. Compounded solutions from unlicensed sources introduce batch-to-batch inconsistency that no amount of careful syringe work can compensate for. Research-grade peptides from Real Peptides deliver exact amino-acid sequencing and verified purity, but the final step. Turning that lyophilised powder into a correctly dosed solution. Is on the researcher. Miss that step and the best peptide in the world delivers unreliable data.

Most peptide protocols fail not because the compound doesn't work, but because the dosing isn't what the researcher thinks it is. A 2mg vial yields 10 doses at 200mcg only if you add exactly 2.0mL bacteriostatic water and draw exactly 0.2mL per administration. Deviate by 5% at either step and your effective dose drifts. Sometimes higher, sometimes lower, always inconsistent. The researchers who get reproducible results across multi-week trials aren't the ones with the fanciest lab equipment. They're the ones who measure reconstitution volume with graduated pipettes, verify syringe draws against a scale when precision matters, and document every deviation from protocol instead of assuming close enough is good enough.

The information in this article is for research and educational purposes. Dosing decisions and peptide handling protocols should align with institutional research guidelines and proper laboratory safety standards.

Syringe Selection and Draw Precision

Insulin syringes are the standard tool for sub-millilitre peptide administration because they're graduated in 0.01mL (1-unit) increments, which is the precision floor for reliable dosing at 100–300mcg target ranges. A 200mcg Hexarelin dose from a 1mg/mL solution requires a 0.2mL draw. That's the 20-unit mark on a standard 0.3mL or 0.5mL insulin syringe. Standard 1mL Luer-lock syringes lack the granularity for this. Their graduations typically jump by 0.1mL, making a 0.15mL draw an approximation rather than a measurement. Approximations compound. Draw 0.18mL when you meant 0.2mL and you've underdosed by 10%. Repeat that across 10 administrations and you've effectively run a different protocol than you documented.

Our experience shows that syringe selection errors are common when researchers transition from mg-range compounds to mcg-range peptides. A researcher accustomed to drawing 0.5mL steroid esters switches to peptides and assumes the same 1mL syringe works. It doesn't, not at the precision peptide dosing requires. Insulin syringes come in three volumes: 0.3mL (30 units), 0.5mL (50 units), and 1.0mL (100 units). For Hexarelin dosing at 100–300mcg, the 0.5mL syringe offers the best balance between precision and draw capacity. The 0.3mL syringe works for single doses up to 0.3mL but limits flexibility if your protocol changes mid-study. The 1.0mL insulin syringe works but adds unnecessary dead space that wastes solution. At 10 doses per vial, even 0.02mL waste per draw costs you a full administration by vial end.

Dead space matters more than most researchers expect. A standard insulin syringe retains approximately 0.01–0.02mL in the hub after injection, which means each administration wastes 10–20mcg of peptide. Over 10 doses, that's 100–200mcg lost. Enough to eliminate one full administration. Low-dead-space syringes reduce this to <0.01mL, recovering nearly a full dose per vial. The cost difference is negligible (low-dead-space syringes run $0.10–0.15 more per unit), but the cumulative peptide recovery across a multi-vial study can justify the switch. For researchers managing tight peptide budgets or running dose-escalation studies where every microgram counts, low-dead-space syringes aren't optional. They're protocol infrastructure. You can explore our full range of research-grade peptides, including options like GHRP-2 and Ipamorelin, to see how precision compounds across your entire peptide toolkit.

Understanding how many doses a vial of Hexarelin yields isn't about memorising a number. It's about recognising that dose count is a calculated output, not a vial property. The 2mg label tells you raw material; your reconstitution volume and target dose tell you how many administrations that material supports. Get the reconstitution right, measure your draws precisely, and a 2mg vial delivers exactly as many doses as the math predicts. Approximate either step and your protocol drifts before the first administration is logged.